-
1.发明授权KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy 有权KDR和VEGF / KDR结合肽及其在诊断和治疗中的应用公开(公告)号：US09446155B2
公开(公告)日：2016-09-20
申请号：US14109508
申请日：2013-12-17
Applicant: Dyax Corp. , BRACCO SUISSE SA
Inventor： Aaron K. Sato , Daniel J. Sexton , Daniel T. Dransfield , Robert Charles Ladner , Christophe Arbogast , Philippe Bussat , Hong Fan , Sudha Khurana , Karen E. Linder , Edmund R. Marinelli , Palaniappa Nanjappan , Adrian D. Nunn , Radhakrishna K. Pillai , Sibylle Pochon , Kondareddiar Ramalingam , Ajay Shrivastava , Bo Song , Rolf E. Swenson , Mathew A. Von Wronski , Feng Yan
CPC classification number: A61K49/221 , A61K38/00 , A61K47/62 , A61K49/223 , A61K51/088 , C07K7/08 , C07K14/001 , C07K14/52 , C07K14/71 , C07K2319/00 , Y02A50/411 , Y02A50/58
Abstract: The present invention provides polypeptides, peptide dimer, and multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a KD
Abstract translation: 本发明提供了包含用于KDR或VEGF / KDR复合物的至少一个结合部分的多肽，肽二聚体和多聚体复合物，其具有各种用途，无论何处治疗，检测，分离或定位血管发生都是有利的。 特别公开的是能够以高亲和力（例如具有KD <1μM）结合KDR或VEGF / KDR复合物的合成，分离的多肽，以及包含这些多肽的二聚体和多聚体构建体。
-
公开(公告)号：US09056138B2
公开(公告)日：2015-06-16
申请号：US14031562
申请日：2013-09-19
Applicant: Bracco Suisse S.A. , Dyax Corp.
Inventor： Hong Fan , Karen E. Linder , Edmund R. Marinelli , Palaniappa Nanjappan , Adrian D. Nunn , Radhakrishna K. Pillai , Kondareddiar Ramalingam , Ajay Shrivastava , Bo Song , Rolf E. Swenson , Mathew A. Von Wronski , Aaron K. Sato , Sharon Michele Walker , Daniel T. Dransfield
CPC classification number: A61K47/48246 , A61K38/16 , A61K47/42 , A61K47/60 , A61K47/64 , A61K49/221 , A61K49/223 , C07K7/08 , C07K7/64 , Y02A50/411
Abstract: The invention provides compositions and methods for therapeutic and diagnostic applications.
Abstract translation: 本发明提供用于治疗和诊断应用的组合物和方法。
-
公开(公告)号：US20140205545A1
公开(公告)日：2014-07-24
申请号：US14031562
申请日：2013-09-19
Applicant: Dyax Corp. , Bracco Suisse S.A.
Inventor： Hong FAN , Karen E. Linder , Edmund R. Marinelli , Palaniappa Nanjappan , Adrian D. Nunn , Radhakrishna K. Pillai , Kondareddiar Ramalingam , Ajay Shrivastava , Bo Song , Rolf E. Swenson , Mathew A. Von Wronski , Aaron K. Sato , Sharon Michele Walker , Daniel T. Dransfield
CPC classification number: A61K47/48246 , A61K38/16 , A61K47/42 , A61K47/60 , A61K47/64 , A61K49/221 , A61K49/223 , C07K7/08 , C07K7/64 , Y02A50/411
Abstract: The invention provides compositions and methods for therapeutic and diagnostic applications.
Abstract translation: 本发明提供用于治疗和诊断应用的组合物和方法。
-
公开(公告)号：US20160222110A1
公开(公告)日：2016-08-04
申请号：US14982649
申请日：2015-12-29
Applicant: DYAX CORP. , BIOGEN HEMOPHILIA INC.
Inventor： Christopher TenHoor , Arumugam Muruganandam , Robert Charles Ladner , Clive Wood , Alan J. Bitonti , James M. McGivney , Kevin A. McDonnell , Liming Liu , Jennifer Dumont , Aaron K. Sato , Malini Viswanathan
Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
-
公开(公告)号：US09260520B2
公开(公告)日：2016-02-16
申请号：US14168839
申请日：2014-01-30
Applicant: DYAX CORP. , BIOGEN HEMOPHILIA INC.
Inventor： Christopher TenHoor , Arumugam Muruganandam , Robert Charles Ladner , Clive Wood , Alan J. Bitonti , James McGivney , Kevin McDonnell , Liming Liu , Jennifer Dumont , Aaron K. Sato , Malini Viswanathan
IPC: C07K16/28 , G01N33/579 , G01N33/68 , A61K39/00
CPC classification number: C07K16/283 , A61K49/0058 , A61K49/16 , A61K51/1027 , A61K2039/505 , C07K16/28 , C07K2317/20 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , G01N33/68 , G01N33/6854 , G01N2333/70535
Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
Abstract translation: 本公开尤其提供结合FcRn的蛋白质，例如以高亲和力和选择性抑制FcRn的免疫球蛋白。 FcRn结合蛋白可用于治疗多种疾病，包括自身免疫性疾病。
-
Patent Agency Ranking
公开(公告)号：US20160222111A1
公开(公告)日：2016-08-04
申请号：US14984075
申请日：2015-12-30
Applicant: DYAX CORP. , BIOGEN HEMOPHILIA INC.
Inventor： Christopher TenHoor , Arumugam Muruganandam , Robert Charles Ladner , Clive Wood , Alan J. Bitonti , James M. McGivney , Kevin A. McDonnell , Liming Liu , Jennifer Dumont , Aaron K. Sato , Malini Viswanathan
IPC: C07K16/28
Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
-
公开(公告)号：US20160222109A1
公开(公告)日：2016-08-04
申请号：US14982521
申请日：2015-12-29
Applicant: DYAX CORP. , Biogen Hemophilia Inc.
Inventor： Christopher TenHoor , Arumugam Muruganandam , Robert Charles Ladner , Clive Wood , Alan J. Bitonti , James M. McGivney , Kevin A. McDonnell , Liming Liu , Jennifer Dumont , Aaron K. Sato , Malini Viswanathan
IPC: C07K16/28
Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
-
公开(公告)号：US20140248287A1
公开(公告)日：2014-09-04
申请号：US14168839
申请日：2014-01-30
Applicant: SYNTONIX PHARMACEUTICALS, INC. , DYAX CORP.
Inventor： Christopher TenHoor , Arumugam Muruganandam , Robert Charles Ladner , Clive Wood , Alan J. Bitonti , James Stattel , Kevin McDonnell , Liming Liu , Jennifer Dumont , Aaron K. Sato , Malini Viswanathan
IPC: C07K16/28
CPC classification number: C07K16/283 , A61K49/0058 , A61K49/16 , A61K51/1027 , A61K2039/505 , C07K16/28 , C07K2317/20 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , G01N33/68 , G01N33/6854 , G01N2333/70535
Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
Abstract translation: 本公开尤其提供结合FcRn的蛋白质，例如以高亲和力和选择性抑制FcRn的免疫球蛋白。 FcRn结合蛋白可用于治疗多种疾病，包括自身免疫性疾病。
-
公开(公告)号：US20160222112A1
公开(公告)日：2016-08-04
申请号：US14984162
申请日：2015-12-30
Applicant: DYAX CORP. , BIOGEN HEMOPHILIA INC.
Inventor： Christopher TenHoor , Arumugam Muruganandam , Robert Charles Ladner , Clive Wood , Alan J. Bitonti , James M. McGivney , Kevin A. McDonnell , Liming Liu , Jennifer Dumont , Aaron K. Sato , Malini Viswanathan
IPC: C07K16/28
Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
-
公开(公告)号：US20160194397A1
公开(公告)日：2016-07-07
申请号：US14985614
申请日：2015-12-31
Applicant: DYAX CORP. , BIOGEN HEMOPHILIA INC.
Inventor： Christopher TenHoor , Arumugam Muruganandam , Robert Charles Ladner , Clive Wood , Alan J. Bitonti , James M. McGivney , Kevin A. McDonnell , Liming Liu , Jennifer Dumont , Aaron K. Sato , Malini Viswanathan
IPC: C07K16/28
Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
-
-
-
-
-
-
-
-
-
Search Results
14
records
(took 0.032 seconds)
